Smartphone-based Cognitive Emotion Regulation Training for Unpaid Primary Caregivers of Persons With Alzheimer's Disease

Biobehavioral Mechanisms of Smartphone-based Cognitive Emotion Regulation Training for Unpaid Primary Caregivers of Persons With Alzheimer's Disease

Alzheimer's Disease (AD) and Alzheimer's Disease-Related Dementias (ADRD) not only exact a heavy toll on patients, they also impose an enormous emotional, physical, and financial burden on unpaid, often family, caregivers. The strain of providing care for a loved one diagnosed with AD, often across several years, is associated with elevated depression risk and poorer overall health. Emotion regulation skills represent an ideal target for psychological intervention to promote healthy coping in ADRD caregivers. The project seeks to use an experimental medicine approach to test the efficacy and biobehavioral mechanisms of a novel, relatively brief, targeted, scalable, smartphone-based cognitive emotion regulation intervention aimed at improving psychological outcomes (i.e., reducing perceived stress, caregiver burden, and depressive symptoms) in ADRD unpaid primary caregivers as well as examine potential benefits of the caregiver intervention on quality of life in care recipients. Cognitive reappraisal is the ability to modify the trajectory of an emotional response by thinking about and appraising emotional information in an alternative, more adaptive way. Reappraisal can be operationalized via two primary tactics: psychological distancing (i.e. appraising an emotional stimulus as an objective, impartial observer) and reinterpretation (i.e., imagining a better outcome than what initially seemed apparent). The project will investigate the efficacy and underlying biobehavioral mechanisms of a novel, one-week cognitive reappraisal intervention in this population, with follow-up assessments at 2 weeks, 4 weeks, and 3 months. ADRD unpaid primary caregivers will be randomly assigned to receive training in either distancing, reinterpretation, or a no regulation natural history control condition, with ecological momentary assessments of self-reported positive and negative affect, remotely- collected psychophysiological health-related biomarkers (i.e., heart rate variability data) using pre-mailed Polar H10 chest bands, and health-related questionnaire reports. Distancing training is expected to result in longitudinal reductions in self-reported negative affect, longitudinal increases in positive affect, and longitudinal increases in HRV that are larger than those attributable to reinterpretation training and no-regulation control training.

Study Overview

• Status: Recruiting
• Conditions: Stress; Emotions; Emotion Regulation; Psychological; Caregivers; Psychophysiology
• Intervention / Treatment: Behavioral: Cognitive Emotion Regulation Training via Psychological Distancing; Behavioral: Cognitive Emotion Regulation Training via Reinterpretation

Detailed Description

The objective of the research is to use an experimental medicine approach to test the efficacy and biobehavioral mechanisms of a novel, relatively brief, targeted, scalable, smartphone-based cognitive emotion regulation intervention aimed at improving psychological outcomes (i.e., reducing perceived stress, caregiver burden, and depressive symptoms) in unpaid primary caregivers of persons diagnosed with Alzheimer's Disease or a related dementia (ADRD) as well as examine potential benefits of the caregiver intervention on quality of life in care recipients. Cognitive reappraisal (i.e., the ability to modify the trajectory of an emotional response by thinking about and appraising emotional information in an alternative, more adaptive way) represents a highly promising target for psychological intervention in ADRD caregivers. Reappraisal can be operationalized via two primary tactics: psychological distancing (i.e. appraising an emotional stimulus as an objective, impartial observer) and reinterpretation (i.e., imagining a better outcome than what initially seemed apparent). The project builds upon promising preliminary work to investigate the efficacy and underlying biobehavioral mechanisms of a novel, one-week cognitive reappraisal intervention in this population. ADRD unpaid primary caregivers will be randomly assigned to receive training in either distancing, reinterpretation, or a no regulation natural history control condition (Look Only), with one-week of active smartphone-based reappraisal training, with follow-up assessments at 2 weeks, 4 weeks, and 3 months, with longitudinal collection of self-reported positive and negative affect, ecological momentary assessments of daily stress, remotely-collected psychophysiological health-related biomarkers (i.e., heart rate variability data collected using a pre-mailed H10 strap and phone app using bluetooth), and health-related questionnaire reports. The study aims to mechanistically relate changes in psychological and psychophysiological function to prediction of health-relevant behavioral outcomes during a novel emotion regulation intervention never before implemented in this stressed, high risk group.

This research represents a Phase I, Stage I clinical trial. The primary endpoints are the assessments of the psychological and psychophysiological mechanisms mediating behavior change as a function of the cognitive emotion regulation intervention. Psychological mechanisms will be assessed by changes in self-reported positive and negative affect. Psychophysiological mechanisms will be investigated by analysis of heart rate variability data. The secondary endpoint is testing the efficacy of the intervention via assessment of psychological outcomes (i.e., the behavior change, as represented in changes in perceived stress, caregiver burden, and depressive symptoms), as well as care recipient quality of life.

270 ADRD unpaid primary caregivers will be recruited to participate in this study. This research involves random assignment of ADRD caregiver participants to either distancing training, reinterpretation training, or a no regulation natural history control condition (Look Only), as described above, using a parallel intervention model. In particular, the investigators will pseudorandomly assign participants to training groups via initially randomly interspersing 270 condition assignments (90 per cell) and then assigning participants in order accordingly. Male ADRD caregivers as well as caregivers from underrepresented racial and ethnic groups will be oversampled to ensure parity of male and female caregivers as well as equitable representation of underrepresented groups in the sample. Trained experimenters from the study team will administer all 3 conditions (distancing, reinterpretation, and Look Only) with equal frequency. The identity of the experimenter will be incorporated as a covariate during data analysis. Fidelity to the experimental protocol will be maintained via a standardized script for emotion regulation training, modified for each of the three conditions (Distancing, Reinterpretation, Look Only); direct PI training of the Project Coordinator and all research assistants who will acquire data on this protocol; and regular adherence monitoring via ongoing PI observation of Project Coordinator and research assistant training implementation. In addition, the investigators will audiotape training sessions (optionally, via informed consent), with PI review of a randomly-selected 10% of recordings to further ensure fidelity to the protocol.

Power Analyses

Power analysis for caregiver self-reported negative affect:

Sufficient power to assess self-reported negative affect outcomes will be achieved by recruiting 90 participants per training condition. This sample size estimate is based upon a power analysis for detecting an approximate effect size (d = 0.5) previously reported for within and between-subjects behavioral analyses of longitudinal reappraisal training data. Power analyses using this approximate effect size indicate over 95% power (alpha = 0.05) to detect within-group effects and over 90% power (alpha = 0.05) to detect between- group effects should be achieved with 70 participants per condition. Assuming all-cause attrition of 20% (which reflects a liberal upper bound, given past participant attrition rates of approximately 10% in longitudinal studies performed by the current study team), the sample size should provide sufficient power to assess this outcome. Post-attrition, the investigators expect to have analyzable complete data for 72-81 participants per condition.

Power analysis for caregiver heart rate variability (HRV):

Sufficient power to assess respiratory sinus arrhythmia outcomes will be achieved by recruiting 90 participants per training condition. This sample size estimate is based upon a power analysis using an approximate effect size (d = 0.5) previously obtained for within and between-subjects analyses of HRV data. Power analyses using this approximate effect size indicate over 95% power (alpha = 0.05) to detect within- group effects and over 90% power (alpha = 0.05) to detect between-group effects should be achieved with 70 participants per condition. Assuming all-cause attrition of 20% (which reflects a liberal upper bound given past participation attrition rates in longitudinal studies performed by the current study team of approximately 10%), the sample size should provide sufficient power to assess this outcome. Post-attrition, the investigators expect to have analyzable complete data for 72-81 participants per condition.

Power analysis for caregiver perceived stress, caregiver burden, depressive symptoms:

Sufficient power to assess questionnaire outcomes (e.g., perceived stress, caregiver burden, depressive symptoms) will be achieved by recruiting 90 participants per training condition. This sample size estimate is based upon a power analysis using an approximate effect size (d = 0.5) previously reported for within and between-subjects analyses of questionnaire reports measuring these variables (e.g., depressive symptoms; perceived stress). Power analyses using this approximate effect size indicate over 95% power (alpha = 0.05) to detect within-group effects and over 90% power (alpha = 0.05) to detect between-group effects should be achieved with 70 participants per condition. Assuming all-cause attrition of 20% (which reflects a liberal upper bound given past participation attrition rates in longitudinal studies performed by the current study team of approximately 10%), the sample size should provide sufficient power to assess this outcome. Post-attrition, the investigators expect to have analyzable complete data for 72-81 participants per condition.

Power analysis for care recipient affect and quality of life:

Sufficient power to assess care recipient affect and quality of life will be achieved by recruiting 90 participants per training condition. While the precise anticipated effect size for change over time in these care recipient measures as a function of caregiver cognitive emotion regulation training is not known and not expected to be large, a power analysis using a small effect size (d = 0.3) indicates 80% power (alpha = 0.05) to detect within-group effects should be achieved with 71 participants per condition. Assuming all-cause attrition of 20% (which reflects a liberal upper bound given past participation attrition rates in longitudinal studies performed by the current study team of approximately 10%), the sample size should provide sufficient power to assess this outcome. Post-attrition, the investigators expect to have analyzable complete data for 72-81 participants per condition.

Data Analyses

Data analysis will primarily use linear mixed models, incorporating fixed effects for Training Group (Distancing, Reinterpretation, No Regulation Control), Session, and Trial Type (for analyses involving the reappraisal task; Look Neutral, Look Negative, and Reappraise Negative), and their fixed-effect interactions, as well as a random effect consisting of an intercept (main effect) for each participant. In an exploratory follow-up, the investigators will additionally examine models using a random slope per participant. The outcome variables will be changes in self-reported positive and negative affect (via EMA) and HRV (RMSSD) (Aim 1) and changes in health-relevant behavioral outcomes (Aim 2). In these analyses, gender, age, caregiver relationship to care recipient, and baseline caregiving distress burden will be incorporated as covariates. Importantly, the investigators also anticipate having sufficient power to conduct exploratory analyses on the effect of caregiver gender and age on the hypothesized effects (all Aims) given that the investigators will ensure gender balance in each group by oversampling male caregivers (see Recruitment and Retention Plan). This information may help inform future intervention design and assessment (Stage II and beyond) that may arise from the results of this work. Aim 3 will be investigated using multilevel mediation modeling involving training group assignment as the higher-level predictor (X); self-reported positive and negative affect, and HRV data as individual-level mediators (M); and health-relevant behavior as individual-level outcome variables (Y; i.e., a 2-1-1 multilevel mediation model). Relevant covariates indicated above will be incorporated in all mediation models.

Missing data will be imputed using random forest imputation, which mines for complexities (interactions, nonlinearities) in the data while achieving more robust cross-validated prediction of missing-at-random (MAR) data. Loss to follow-up will be mitigated via systematic tracking of participant progress during the experiment (e.g., timeliness and completeness of training via Qualtrics from T1-T7; completion rate for daily EMA pings; and timeliness and completeness of questionnaires). An experimenter will directly contact participants who do not complete study components on schedule (i.e., not completing daily training, responding to fewer than 1 EMA ping per day, or not completing questionnaires on schedule) with reminders about the study schedule and assist with any questions. This checking and reminder system will be in addition to the automated SMS reminders sent via SurveySignal.

• Study Type: Interventional
• Enrollment (Estimated): 270
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Bryan Denny, Ph.D.; Phone Number: 713-348-8257; Email: btd3@rice.edu

Study Locations

• United States
  • Texas
    • Houston, Texas, United States, 77030
      • Recruiting
      • Rice University
      • Contact: Bryan T Denny, PhD; Phone Number: 713-348-8257; Email: btd3@rice.edu
      • Principal Investigator: Bryan T Denny, PhD
      • Contact: Nia Walls, BA; Phone Number: 713-348-8246; Email: nw28@rice.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

Healthy Adult Caregivers

• Unpaid primary caregiver of patient with Alzheimer's Disease/Alzheimer's Disease and Related Dementias (AD/ADRD)
• At least 18 years of age, with no maximum age, provided that all other inclusion/exclusion criteria are met
• Must be able to speak, read, and write in English
• Must be free of any current or past DSM diagnosis (i.e. healthy adults), with the exception of current or past mood or anxiety disorders or past substance-related disorders (i.e., current or past mood or anxiety disorders and/or past substance-related disorders would not represent an exclusion factor)
• Must have a smartphone. This represents any major iOS or Android-based smartphone. The smartphone will also be used for collection of ecological momentary assessment (EMA) data via SurveySignal.
• Must provide at least 4 hours of active caregiving a day to their care recipient in the care recipient's home
• Must be at least minimally-stressed (i.e., CES-D score of at least 16)

Cognitively Impaired Adults

• Must have diagnosed with Alzheimer's Disease/Alzheimer's Disease and Related Dementias (AD/ADRD)
• Must be the care recipient of the primary caregiver who is completing the study
• Must be able to understand and willing to complete a questionnaire and the consent form
• Must have a Quick Dementia Rating System (QDRS) rating of at least 6

Exclusion Criteria:

Healthy Adult Caregivers

• Current or past DSM diagnosis, with the exception of current or past mood or anxiety disorders or past substance-related disorders (i.e., current or past mood or anxiety disorders and/or past substance-related disorders would not represent an exclusion factor)
• Currently receiving psychotherapy that specifically addresses caregiver burden/distress or employs cognitive reappraisal as a major component
• Significant visual, auditory, or cognitive impairment that compromises their ability to understand and complete the task
• Caregiver participants who cease meeting inclusion criteria during the study (e.g., if the care recipient enters a skilled nursing facility during the study and inclusion criteria above are no longer met) will be dismissed from the study and compensated pro-rata.
• Has formerly participated in a study from our lab involving the same or essentially same design (e.g., former participants who provided pilot/preliminary data for this study)

Cognitively Impaired Adults

• The care recipient does not wish to participate, and/or their caregiver does not want them to participate
• Significant visual, auditory, or cognitive impairment that compromises their ability to understand and complete questionnaires, even with their caregiver's help will exclude them from the study
• Has formerly participated in a study from our lab involving the same or essentially same design (e.g., former participants who provided pilot/preliminary data for this study)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Distancing; Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction via videoconference in which detailed instructions for implementation of the distancing strategy is explained (i.e. appraising an emotional stimulus as an objective, impartial observer).	Behavioral: Cognitive Emotion Regulation Training via Psychological Distancing; The project will randomly assign Alzheimer's Disease or related dementia (AD/ADRD) unpaid primary caregivers to receive a brief course of reappraisal training using either psychological distancing or reinterpretation, or to a no regulation natural history control condition. In the Psychological Distancing group, participants will be asked to down-regulate negative emotion by reappraising an emotional stimulus as an objective, impartial observer.
Active Comparator: Reinterpretation; Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction via videoconference in which detailed instructions for implementation of the reinterpretation strategy is explained (i.e. imagining a better outcome than what initially seemed apparent).	Behavioral: Cognitive Emotion Regulation Training via Reinterpretation; The project will randomly assign Alzheimer's Disease or related dementia (AD/ADRD) unpaid primary caregivers to receive a brief course of reappraisal training using either psychological distancing or reinterpretation, or to a no regulation natural history control condition. In the Reinterpretation group, participants will be asked to down-regulate negative emotion by imagining a better outcome (when engaging with an emotional stimulus) than what initially seemed apparent.
No Intervention: No regulation "Look Only"; The No Regulation "Look Only" Control group will serve as a habituation and natural history control; they will see the same emotional images, but they will only be cued to look and respond naturally for all trials.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Self-reported negative affect	Self-reported negative affect data collected during completion of emotion regulation task via smartphone	During Sessions Day 1 - Day 7; this cycle is 7 days
Ecological momentary assessment of positive and negative affect	Ecological momentary assessment (EMA) of positive and negative affect collected during 4 daily afternoon EMA pings via smartphone	During Sessions Day 1 - Day 7; this cycle is 7 days
Heart rate variability	Heart rate variability measured via smartphone in conjunction with a Bluetooth-connected H10 Polar Chest Band. Change in heart rate variability assessed at the following timepoints:	Initial training (Day 0), Day 7, Day 14, Day 28, and Month 3
Perceived stress	Perceived stress assessed via the Perceived Stress Scale on a scale of 0 to 4, with 0 indicating "Never" and 4 indicating "Very Often". A higher overall score on the stress scale indicates a worse outcome. Change in self-reports of perceived stress assessed at the following timepoints:	Initial training (Day 0), Day 7, Day 14, Day 28, and Month 3
Caregiver burden	Caregiver burden assessed via the Caregiver Burden Scale on a scale of 0 to 4, with 0 indicating "Never" and 4 indicating "Nearly Always". The greater the total score, the worse the outcome. Change in self-reports of caregiver burden assessed at the following timepoints:	Initial training (Day 0), Day 7, Day 14, Day 28, and Month 3
Caregiver quality of life	Caregiver quality of life assessed via the Caregiver Quality of Life Index on a scale of 0 to 4, with 0 indicating "Not at all" and 4 indicating "Very much". A higher overall score on the Caregiver quality of life index indicates a higher quality of life and better outcome. Change in self-reports of caregiver quality of life assessed at the following timepoints:	Initial training (Day 0), Day 7, Day 14, Day 28, and Month 3
Depressive symptoms	Depressive systems assessed via the Center for Epidemiological Studies-Depression (CES-D) Depression Inventory on a scale of 0 to 3, with 0 indicating "Rarely or none of the time (less than 1 day)," and 3 indicating "Most or all of the time (5-7 days)". The higher the score on the CES-D Depression Inventory, the worse the outcome. Change in self-reports of depressive symptoms assessed at the following timepoints:	Initial training (Day 0), Day 7, Day 14, Day 28, and Month 3
Difficulty in regulating emotion	Difficulty in regulating emotion will be assessed using the Difficulties in Emotion Regulation Scale - Short Form (DERS-SF). There are 5 possible responses to a series of questions: almost never (0-10%), sometimes (11-35%), about half of the time (36-65), most of the time (66%-90%), almost always (91-100%). "Almost never" is the minimum score and "almost always) is the maximum score. Higher scores reflect a worse outcome or greater difficulty with emotion regulation. Change in self-reports of regulating emotions assessed at the following timepoints:	Initial training (Day 0), Day 7, Day 14, Day 28, and Month 3
Positive and negative affect	Positive and negative affect assessed via the Positive and Negative Affect Schedule (PANAS) on a scale of 1 to 5, with a score of 1 indicating "Very slightly or not at all" and a score of 5 indicating "extremely". It is scored using two categories, a positive affect score and a negative affect score. Those with a higher positive affect and lower negative affect score have the most positive outcome. Change in self-reports of positive and negative affect assessed at the following timepoints:	Initial training (Day 0), Day 7, Day 14, Day 28, and Month 3
Interpersonal regulation	Interpersonal regulation efficacy assessed via the Interpersonal Regulation Questionnaire on a scale of 1 to 7, with a score of 1 indicating "strongly disagree" and a scale of 7 indicating "strongly agree". A higher score on this questionnaire indicates a change in self-reports of interpersonal regulation assessed at the following timepoints:	Initial training (Day 0), Day 7, Day 14, Day 28, and Month 3
Empathy	Empathy Assessed via the Interpersonal Reactivity Index (IRI) on a scale of 0 to 4, with a score of 0 indicating "does not describe me well" and a score of 4 indicating "describes very well". A higher score on this index indicates greater levels of empathy. In this study, the degree of empathy the individual scores does not correlate to a better or worse outcome. The Change in self-reports of empathy assessed at the following timepoints:	Initial training (Day 0), Day 7, Day 14, Day 28, and Month 3

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reappraisal usage frequency	General/overall reappraisal usage frequency assessed via the Emotion Regulation Questionnaire	Initial training (Day 0)
Reappraisal usage frequency	General/overall reappraisal usage frequency assessed via the Emotion Regulation Questionnaire	Day 7
Reappraisal usage frequency	General/overall reappraisal usage frequency assessed via the Emotion Regulation Questionnaire	Day 14
Reappraisal usage frequency	General/overall reappraisal usage frequency assessed via the Emotion Regulation Questionnaire	Day 28
Reappraisal usage frequency	General/overall reappraisal usage frequency assessed via the Emotion Regulation Questionnaire	Month 3; this period one day long, 3 months after the initial visit)
Quick Dementia Rating System (QDRS)	Caregiver-reported assessment of cognitive and behavioral function of care recipients. The QDRS is scored on a continuous scale with a range of 0-30. Higher scores suggest more impairment.	Initial training (Day 0)
Quick Dementia Rating System (QDRS)	Caregiver-reported assessment of cognitive and behavioral function of care recipients. The QDRS is scored on a continuous scale with a range of 0-30. Higher scores suggest more impairment.	Day 7
Quick Dementia Rating System (QDRS)	Caregiver-reported assessment of cognitive and behavioral function of care recipients. The QDRS is scored on a continuous scale with a range of 0-30. Higher scores suggest more impairment.	Day 14
Quick Dementia Rating System (QDRS)	Caregiver-reported assessment of cognitive and behavioral function of care recipients. The QDRS is scored on a continuous scale with a range of 0-30. Higher scores suggest more impairment.	Day 28
Quick Dementia Rating System (QDRS)	Caregiver-reported assessment of cognitive and behavioral function of care recipients. The QDRS is scored on a continuous scale with a range of 0-30. Higher scores suggest more impairment.	Month 3 (this period is one day long, 3 months after the initial visit)
Revised Memory and Behavior Problem Checklist (RMBPC)	The Revised Memory and Behavior Problem Checklist involves the caregiver a) rating the frequency of observable behavior problems in the dementia patient during the past week (1 = not in the past week, to 4 = daily or more often) and (b) their reaction to each behavior (e.g. how bothered or upset the caregiver feels when the behavior occurs with 0 = not at all to 4 = extremely). Frequency Score: The total frequency score is computed to obtain a possible range of 0 to 4, where 0 is the lowest frequency of behavioral problems, and 4 is the highest frequency. Reaction Scoring: The total reaction score is computed in the same way, to obtain a possible range of 0 to 4, where 0 as the minimum reaction score (e.g., not being upset about the care recipient's behavioral problems) and 4 as the maximum reaction score (e.g., being extremely upset about the care recipient's behavioral problems).	Month 3 (this period is one day long, 3 months after the initial visit)
Care recipient affect	Care recipients will provide valence and arousal ratings by selecting the Self-Assessment Manikin that best exemplifies their emotional state in that moment. Their arousal rating is selected between 9 Manikins that range from a frowning face to a smiling face, with less arousal indicated by a frowning face and greater arousal indicated by a smiling face. Their valence rating is selected between 9 Manikins that range from a small bubble in their chest to a large, protruding bubble in their chest. The lower their valence rating is, the smaller the chest bubble appears. Change in self-reports of valence and arousal assessed at the following timepoints:	Initial training (Day 0)
Care recipient affect	Care recipients will provide valence and arousal ratings by selecting the Self-Assessment Manikin that best exemplifies their emotional state in that moment. Their arousal rating is selected between 9 Manikins that range from a frowning face to a smiling face, with less arousal indicated by a frowning face and greater arousal indicated by a smiling face. Their valence rating is selected between 9 Manikins that range from a small bubble in their chest to a large, protruding bubble in their chest. The lower their valence rating is, the smaller the chest bubble appears. Change in self-reports of valence and arousal assessed at the following timepoints:	Day 7
Care recipient affect	Care recipients will provide valence and arousal ratings by selecting the Self-Assessment Manikin that best exemplifies their emotional state in that moment. Their arousal rating is selected between 9 Manikins that range from a frowning face to a smiling face, with less arousal indicated by a frowning face and greater arousal indicated by a smiling face. Their valence rating is selected between 9 Manikins that range from a small bubble in their chest to a large, protruding bubble in their chest. The lower their valence rating is, the smaller the chest bubble appears. Change in self-reports of valence and arousal assessed at the following timepoints:	Day 14
Care recipient affect	Care recipients will provide valence and arousal ratings by selecting the Self-Assessment Manikin that best exemplifies their emotional state in that moment. Their arousal rating is selected between 9 Manikins that range from a frowning face to a smiling face, with less arousal indicated by a frowning face and greater arousal indicated by a smiling face. Their valence rating is selected between 9 Manikins that range from a small bubble in their chest to a large, protruding bubble in their chest. The lower their valence rating is, the smaller the chest bubble appears. Change in self-reports of valence and arousal assessed at the following timepoints:	Day 28
Care recipient affect	Care recipients will provide valence and arousal ratings by selecting the Self-Assessment Manikin that best exemplifies their emotional state in that moment. Their arousal rating is selected between 9 Manikins that range from a frowning face to a smiling face, with less arousal indicated by a frowning face and greater arousal indicated by a smiling face. Their valence rating is selected between 9 Manikins that range from a small bubble in their chest to a large, protruding bubble in their chest. The lower their valence rating is, the smaller the chest bubble appears. Change in self-reports of valence and arousal assessed at the following timepoints:	Month 3 (this period is one day long, 3 months after the initial visit)
Care recipient quality of life	Care recipients will rate their quality of life using the Quality of Life in Alzheimer's Disease Scale (QoL-AD). There are 4 possible responses to a series of questions: poor, fair, good, and excellent. "Poor" is the minimum score and "excellent" is the maximum score. Higher scores mean a better outcome or greater quality of life. Change in self-reports of care recipient quality of life at the following timepoints:	Initial training (Day 0)
Care recipient quality of life	Care recipients will rate their quality of life using the Quality of Life in Alzheimer's Disease Scale (QoL-AD). There are 4 possible responses to a series of questions: poor, fair, good, and excellent. "Poor" is the minimum score and "excellent" is the maximum score. Higher scores mean a better outcome or greater quality of life. Change in self-reports of care recipient quality of life at the following timepoints:	Day 7
Care recipient quality of life	Care recipients will rate their quality of life using the Quality of Life in Alzheimer's Disease Scale (QoL-AD). There are 4 possible responses to a series of questions: poor, fair, good, and excellent. "Poor" is the minimum score and "excellent" is the maximum score. Higher scores mean a better outcome or greater quality of life. Change in self-reports of care recipient quality of life at the following timepoints:	Day 14
Care recipient quality of life	Care recipients will rate their quality of life using the Quality of Life in Alzheimer's Disease Scale (QoL-AD). There are 4 possible responses to a series of questions: poor, fair, good, and excellent. "Poor" is the minimum score and "excellent" is the maximum score. Higher scores mean a better outcome or greater quality of life. Change in self-reports of care recipient quality of life at the following timepoints:	Day 28
Care recipient quality of life	Care recipients will rate their quality of life using the Quality of Life in Alzheimer's Disease Scale (QoL-AD). There are 4 possible responses to a series of questions: poor, fair, good, and excellent. "Poor" is the minimum score and "excellent" is the maximum score. Higher scores mean a better outcome or greater quality of life. Change in self-reports of care recipient quality of life at the following timepoints:	Month 3 (this period is one day long, 3 months after the initial visit)

Collaborators and Investigators

• Sponsor: Bryan Denny
• Collaborators: National Institute on Aging (NIA)
• Investigators: Principal Investigator: Bryan Denny, Ph.D., William Marsh Rice University

Publications and helpful links

General Publications

• Godwin KM, Mills WL, Anderson JA, Kunik ME. Technology-driven interventions for caregivers of persons with dementia: a systematic review. Am J Alzheimers Dis Other Demen. 2013 May;28(3):216-22. doi: 10.1177/1533317513481091. Epub 2013 Mar 25.
• Denny BT, Ochsner KN. Behavioral effects of longitudinal training in cognitive reappraisal. Emotion. 2014 Apr;14(2):425-33. doi: 10.1037/a0035276. Epub 2013 Dec 23.
• Denny BT. Getting better over time: A framework for examining the impact of emotion regulation training. Emotion. 2020 Feb;20(1):110-114. doi: 10.1037/emo0000641.
• Butler, M., J.E. Gaugler, K.M.C. Talley, H.I. Abdi, P.J. Desai, S. Duval, M.L. Fort, V.A. Nelson, W. Ng, J.M. Ouellette, E. Ratner, J. Saha, T. Shippee, B.L. Wagner, T.J. Wilt, and L. Yeshi, Care Interventions for People Living With Dementia and Their Caregivers. Comparative Effectiveness Review No. 231. (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-2015- 00008-I.) AHRQ Publication No. 20-EHC023. 2020: Rockville, MD.
• Brewster P, Barnes L, Haan M, Johnson JK, Manly JJ, Napoles AM, Whitmer RA, Carvajal-Carmona L, Early D, Farias S, Mayeda ER, Melrose R, Meyer OL, Zeki Al Hazzouri A, Hinton L, Mungas D. Progress and future challenges in aging and diversity research in the United States. Alzheimers Dement. 2019 Jul;15(7):995-1003. doi: 10.1016/j.jalz.2018.07.221. Epub 2018 Sep 19.
• Boots LM, de Vugt ME, van Knippenberg RJ, Kempen GI, Verhey FR. A systematic review of Internet-based supportive interventions for caregivers of patients with dementia. Int J Geriatr Psychiatry. 2014 Apr;29(4):331-44. doi: 10.1002/gps.4016. Epub 2013 Aug 20.
• Schulz R. The Future of Caregiver Efficacy Research: Commentary on "Long-Term Outcomes of the Benefit-Finding Group Intervention for Alzheimer Family Caregivers". Am J Geriatr Psychiatry. 2019 Sep;27(9):995-997. doi: 10.1016/j.jagp.2019.04.001. Epub 2019 Apr 10. No abstract available.
• Berking M, Ebert D, Cuijpers P, Hofmann SG. Emotion regulation skills training enhances the efficacy of inpatient cognitive behavioral therapy for major depressive disorder: a randomized controlled trial. Psychother Psychosom. 2013;82(4):234-45. doi: 10.1159/000348448. Epub 2013 May 22.
• Berking M, Wupperman P, Reichardt A, Pejic T, Dippel A, Znoj H. Emotion-regulation skills as a treatment target in psychotherapy. Behav Res Ther. 2008 Nov;46(11):1230-7. doi: 10.1016/j.brat.2008.08.005. Epub 2008 Aug 30.

Study record dates

Study Major Dates

• Study Start (Actual): September 14, 2023
• Primary Completion (Estimated): November 30, 2026
• Study Completion (Estimated): May 31, 2027

Study Registration Dates

• First Submitted: April 10, 2023
• First Submitted That Met QC Criteria: July 14, 2023
• First Posted (Actual): July 17, 2023

Study Record Updates

• Last Update Posted (Estimated): December 4, 2023
• Last Update Submitted That Met QC Criteria: November 30, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: caregiving; psychophysiology; emotion regulation; psychoneuroimmunology; affective science
• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Dementia; Tauopathies; Alzheimer Disease
• Other Study ID Numbers: IRB-FY2018-336; 1R01AG074229-01A1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Pursuant to the NIH Data Sharing Policy, we have created a Data Sharing Plan for the project. Under this plan, and pursuant to IRB regulations at Rice University and Baylor College of Medicine, fully de-identified raw data (defined below) will be made publicly available through the mechanisms below after the analysis process is complete and research manuscript(s) are finalized. Available data will include a compendium of de-identified training condition assignments; raw (i.e. individual subject-by-condition level) negative affect self-reports; ecological momentary assessment (EMA) reports; questionnaire data; and raw heart rate variability data. All datafiles will be uploaded to the Open Science Framework, a free, open-science data repository.
• IPD Sharing Time Frame: De-identified data will be made available after the analysis process is complete and research manuscripts are finalized. There is no fixed end date for data access.
• IPD Sharing Access Criteria: Data will be publicly available on the Open Science Framework (https://osf.io), a free, open-science data repository.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No